Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Severe Adolescent Depression
NCT03889756Phase 3Terminated
- Sponsor
- Yale University
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ketamine in major depressive disorder (MDD), sponsored by Yale University. Started Jul 2019; status: terminated.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03889756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03889756.